Evidence map›Paper›PMID 29460266›Full record

ArticleMolecular neurobiology2018

Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration.

Jordi Creus-Muncunill, Laura Rué, Rafael Alcalá-Vida, Raquel Badillos-Rodríguez, Joan Romaní-Aumedes, Sonia Marco, Jordi Alberch, Isabel Perez-Otaño, Cristina Malagelada, Esther Pérez-Navarro

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jordi Creus-MuncunillDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, E-08036, Barcelona, Catalonia, Spain.
Laura RuéDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, E-08036, Barcelona, Catalonia, Spain.
Rafael Alcalá-VidaDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, E-08036, Barcelona, Catalonia, Spain.
Raquel Badillos-RodríguezDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, E-08036, Barcelona, Catalonia, Spain.
Joan Romaní-AumedesDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, E-08036, Barcelona, Catalonia, Spain.
Sonia MarcoLaboratorio de Neurobiología Celular, Centro de Investigación Médica Aplicada y Universidad de Navarra, Pamplona, Spain.
Jordi AlberchDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, E-08036, Barcelona, Catalonia, Spain.
Isabel Perez-OtañoLaboratorio de Neurobiología Celular, Centro de Investigación Médica Aplicada y Universidad de Navarra, Pamplona, Spain.
Cristina MalageladaDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, E-08036, Barcelona, Catalonia, Spain.
Esther Pérez-NavarroDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, E-08036, Barcelona, Catalonia, Spain. estherperez@ub.edu.ORCID http://orcid.org/0000-0001-9165-6539
Biomedical Research Networking Center on Neurodegenerative Diseases · ESDepartament de Salut · ESUniversidad de Navarra · ES

Funding

FP7 People: Marie-Curie Actions PIRG08-GA-2010-276957Instituto de Salud Carlos III PI13/01250Ministerio de Economia y Competitividad CSD2008-00005Ministerio de Economia y Competitividad SAF2010-21058Ministerio de Economia y Competitividad SAF2013-48983-RMinisterio de Economia y Competitividad SAF2016-08573-RMinistrio de Economia y Competitividad SAF2013-45888R
6 · The paper itself

Abstract

Rictor associates with mTOR to form the mTORC2 complex, which activity regulates neuronal function and survival. Neurodegenerative diseases are characterized by the presence of neuronal dysfunction and cell death in specific brain regions such as for example Huntington's disease (HD), which is characterized by the loss of striatal projection neurons leading to motor dysfunction. Although HD is caused by the expression of mutant huntingtin, cell death occurs gradually suggesting that neurons have the capability to activate compensatory mechanisms to deal with neuronal dysfunction and later cell death. Here, we analyzed whether mTORC2 activity could be altered by the presence of mutant huntingtin. We observed that Rictor levels are specifically increased in the striatum of HD mouse models and in the putamen of HD patients. Rictor-mTOR interaction and the phosphorylation levels of Akt, one of the targets of the mTORC2 complex, were increased in the striatum of the R6/1 mouse model of HD suggesting increased mTORC2 signaling. Interestingly, acute downregulation of Rictor in striatal cells in vitro reduced mTORC2 activity, as shown by reduced levels of phospho-Akt, and increased mutant huntingtin-induced cell death. Accordingly, overexpression of Rictor increased mTORC2 activity counteracting cell death. Furthermore, normalization of endogenous Rictor levels in the striatum of R6/1 mouse worsened motor symptoms suggesting an induction of neuronal dysfunction. In conclusion, our results suggest that increased Rictor striatal levels could counteract neuronal dysfunction induced by mutant huntingtin.

Indexed as

AnimalsCell DeathDependovirusDisease Models, AnimalGene Knockdown TechniquesHumansHuntingtin ProteinHuntington DiseaseMaleMechanistic Target of Rapamycin Complex 2MiceMotor ActivityMutant ProteinsNeostriatumNerve DegenerationRapamycin-Insensitive Companion of mTOR ProteinHTT protein, humanHtt protein, mouseHuntingtin ProteinMechanistic Target of Rapamycin Complex 2Mutant ProteinsRapamycin-Insensitive Companion of mTOR ProteinRICTOR protein, humanrictor protein, mouseTOR Serine-Threonine KinasesAktmTORRaptorS6KStriatum

Identifiers

PMID29460266
OpenAlexW2792289924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.